05/13/2025
6:35 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/01/2025
3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/25/2025
7:02 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/15/2025
7:00 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
04/14/2025
3:10 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/24/2025
3:40 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/24/2025
3:44 PM | Adaptimmune Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/20/2025
6:09 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2025
4:34 PM | Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:35 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:30 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ADAP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
02/20/2025
4:31 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:32 PM | Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:33 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
8:31 AM | Adaptimmune Therapeutics (Subject)
Two Seas Capital LP (Filed by)
| Form SCHEDULE 13G | |
02/12/2025
9:25 AM | Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
| Form SCHEDULE 13G/A | |
01/17/2025
8:15 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:16 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:17 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:17 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
2:07 PM | Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:42 PM | Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:50 PM | Adaptimmune Therapeutics (Subject)
Bertrand William C JR (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:59 PM | Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
3:15 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:16 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:17 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:18 PM | Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:19 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
2:43 PM | Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
2:50 PM | Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
2:34 PM | Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025
9:30 AM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
12/19/2024
6:40 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
4:17 PM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
11/13/2024
8:04 AM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
8:10 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
4:00 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2024
6:23 AM | Adaptimmune Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/12/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
F1 Engineering Powers This Electric Marine Motor (Ad) The future of marine propulsion has arrived - powered by F-1 grade engineering.
In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry. How one NASDAQ-listed disruptor is bringing the world's most powerful electric marine powertrain to |
08/02/2024
6:00 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/16/2024
3:30 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
